Artiva Biotherapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 27, 2026, 8:30 a.m. ETView on SEC.gov
Results of operations and financial condition · Costs of exit or disposal activities · Financial statements and exhibits
AI summary, unreviewedArtiva Biotherapeutics halts AlloNK development, cuts workforce by 94% and explores strategic alternatives; preliminary cash $319.1 million
4Oct. 7, 2026, 4:02 p.m. ETView on SEC.gov
4Oct. 6, 2026, 4:02 p.m. ETView on SEC.gov
4Oct. 6, 2026, 4:02 p.m. ETView on SEC.gov
4Oct. 6, 2026, 4:02 p.m. ETView on SEC.gov
4Oct. 6, 2026, 4:01 p.m. ETView on SEC.gov
4Sept. 15, 2026, 4:44 p.m. ETView on SEC.gov
4Sept. 14, 2026, 6:46 p.m. ETView on SEC.gov
4Sept. 14, 2026, 8:07 p.m. ETView on SEC.gov
4Sept. 14, 2026, 4:05 p.m. ETView on SEC.gov
4Sept. 14, 2026, 4:04 p.m. ETView on SEC.gov
4Sept. 14, 2026, 4:04 p.m. ETView on SEC.gov
4Sept. 14, 2026, 4:03 p.m. ETView on SEC.gov
4Sept. 14, 2026, 4:03 p.m. ETView on SEC.gov
4Sept. 14, 2026, 4:02 p.m. ETView on SEC.gov
4Sept. 11, 2026, 6:37 p.m. ETView on SEC.gov
4Sept. 11, 2026, 6:36 p.m. ETView on SEC.gov
4Sept. 11, 2026, 6:36 p.m. ETView on SEC.gov
4Sept. 11, 2026, 6:35 p.m. ETView on SEC.gov
8-KSept. 11, 2026, 4:21 p.m. ETView on SEC.gov
Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Financial statements and exhibits
4Sept. 9, 2026, 4:02 p.m. ETView on SEC.gov
4Sept. 8, 2026, 6:29 p.m. ETView on SEC.gov
4Sept. 8, 2026, 5:58 p.m. ETView on SEC.gov
4Sept. 8, 2026, 5:57 p.m. ETView on SEC.gov
4Sept. 8, 2026, 5:56 p.m. ETView on SEC.gov
4Sept. 8, 2026, 5:56 p.m. ETView on SEC.gov
4Sept. 8, 2026, 5:55 p.m. ETView on SEC.gov
4Sept. 8, 2026, 5:55 p.m. ETView on SEC.gov
4Sept. 4, 2026, 4:04 p.m. ETView on SEC.gov
4Sept. 4, 2026, 4:03 p.m. ETView on SEC.gov